US 10,543,179 B2 | Dosage regimen of an S1P receptor modulator

Please sign up or log in to access the advanced features of
Ex Parte Enterprise.

or Log in

General

US 10,543,179 B2

Dosage regimen of an S1P receptor modulator

Tech Center:

1600 Biotechnology and Organic Chemistry

Examiner:

David Browe

Art Unit:

1617 Organic Compounds: Bio-affecting, Body Treating, Drug Delivery, Steroids, Herbicides, Pesticides, Cosmetics, and Drugs

Agent:

Baker Donelson

Inventors:

Craig Boulton; Pascale BURTIN; Olivier DAVID; Ana de VERA; Thomas DUMORTIER; Irene HUNT; Robert SCHMOUDER; William C. COLLINS

Assignee:

NOVARTIS PHARMACEUTICALS CORPORATION

Priority:

09/29/09

Filed:

05/23/18

Granted:

01/28/20

Expiration:

09/29/29

Abstract

The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disorder, for example multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection and vaccinating the patient prior to administration of fingolimod or a pharmaceutically acceptable salt thereof at a daily dosage of 0.5 mg.

General

Analytics

Cases

Patent Assignments

Citations